Trial Profile

Reservoir-Based Polymer-Free Amphilimus-Eluting Stent Versus Polymer-Based Everolimus-Eluting Stent in Diabetic Patients (RESERVOIR) Trial

Status: Active, no longer recruiting

Phase of Trial: Phase III

Latest Information Update: 22 Oct 2015

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Sirolimus (Primary) ; Everolimus
Indications Angina pectoris; Coronary artery disease; Coronary artery restenosis; Myocardial infarction; Thrombosis; Venous thromboembolism
Focus Therapeutic Use
Acronyms RESERVOIR

Most Recent Events

02 Sep 2015 Results (n=101 lesions) presented at the ESC Congress 2015: Annual Congress of the European Society of Cardiology
05 Nov 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
22 Aug 2013 Planned End Date changed from 1 Jan 2014 to 1 Oct 2014 as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com